Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY.

@article{Freda2015LongtermTW,
  title={Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY.},
  author={Pamela U. Freda and Murray B Gordon and Nicky Kelepouris and Peter Jonsson and Maria Koltowska-Haggstrom and Aart Jan van der Lely},
  journal={Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists},
  year={2015},
  volume={21 3},
  pages={264-74}
}
OBJECTIVE To evaluate use of pegvisomant, a growth hormone (GH) receptor antagonist, as monotherapy in ACROSTUDY, a global safety surveillance study set in 14 countries (373 sites). METHODS A descriptive analysis of safety, magnetic resonance imaging (MRI) reading, and treatment outcomes in 710 subjects who received at least 1 pegvisomant dose as monotherapy during and up to 5 years follow-up in ACROSTUDY. RESULTS Subjects received a mean of 5.4 years of pegvisomant and were followed in… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

60 YEARS OF NEUROENDOCRINOLOGY: Acromegaly.

The Journal of endocrinology • 2015
View 3 Excerpts
Highly Influenced

Medical Treatment for Acromegaly does not Increase the Risk of Central Adrenal Insufficiency: A Long-Term Follow-Up Study.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme • 2016

Pegvisomant: Balance after 10 years.

Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion • 2015

Similar Papers

Loading similar papers…